The transmission of Pneumocystis carinii from person to person was studied by detecting P. carinii-specific DNA in prospectively obtained noninvasive deep-nasal-swab samples from a child with a documented P. carinii pneumonia (PCP), his mother, two contact health care workers, and 30 hospital staff members who did not enter the patient's room (controls). Nested-DNA amplification was done by using oligonucleotide primers designed for the gene encoding the mitochondrial large subunit rRNA of rat P. carinii (P. carinii f. sp. carinii) that amplifies all forms of P. carinii and internal primers specific for human P. carinii (f. sp. hominis). P. carinii f. sp. hominis DNA was detected in samples from the patient and all of his contacts versus none of the 30 hospital staff members. The results, as previously shown in murine models of P. carinii pneumonia, document that person-to-person transmission of P. carinii is possible. This observation suggests that immunocompromised patients not on PCP prophylaxis should not enter the room of a patient with PCP, and it also raises the question as to whether healthy contacts can transmit the disease to immunocompromised patients at risk.
Clusters of Pneumocystis carinii pneumonia (PCP) cases have been reported in wards of immunocompromised patients, suggesting the person-to-person transmission of P. carinii (2, 6, 8, 12, 13) . This form of transmission is also suggested by the documentation of a rise in P. carinii antibodies in the contacts of patients with P. carinii pneumonia (J. A. Giron, S. Martinez, and P. D. Walzer, Letter, Lancet ii:46, 1982) and by animal models in a controlled environment showing that P. carinii can be transmitted through the airborne route (7) . The recent finding that P. carinii DNA can be detected in the room air of patients with PCP (1) led us to hypothesize that P. carinii DNA could be detected with the use of highly sensitive nested-DNA amplification technology in deep-nasal-swab samples from a patient with PCP and his contact health care workers. Hospital staff members who did not enter the patient's room were selected as controls. Our results show that P. carinii DNA can be transiently detected in immunocompetent close contacts of patients with PCP and raises the possibility that such contacts might serve as vectors for transmission of the disease.
MATERIALS AND METHODS
Index patient, contacts, and controls. An 8-month-old human immunodeficiency virus-negative boy was referred from a rural hospital with a 1-week history of mild cough and a 4-day history of intermittent fever up to 38.5°C. His past medical history revealed recurrent episodes of oral and esophageal candidiasis starting at the age of 3 months. Upon admission the infant presented with extensive white plaques in the oral cavity, mouth breathing, mild nonproductive cough, a respiratory rate of 45/min, and a pulse oximetry of 85% on room air. His lung examination revealed coarse breath sounds with no wheezes, rhonchi, or rales. Chest radiography showed extensive bilateral infiltrates. Laboratory tests showed depressed T-cell counts (white cells, 4 , 25 mg/dl; IgG, 720 mg/dl; IgM, 68 mg/dl). The infant was admitted with a diagnosis of pneumonia to a single, standard, hospital room without a controlled environment. The diagnosis of PCP was documented by a Gomori-Grocott stain of the bronchoalveolar lavage fluid performed 2 days after admission, and specific chemotherapy was started (day 1; Fig. 1 ) with trimethoprim-sulfamethoxazole (20 mg of trimethoprim component per kg per day) given intravenously in four divided doses. He received supplemental oxygen (1 liter/min) via a nasal catheter during the first 2 weeks of hospitalization and subsequently improved without requiring mechanical ventilation. He was discharged from the hospital after 48 days. There were no other patients with P. carinii infection identified in this pediatric hospital during the time of the study. The mother of the patient, the attending physician, and one nurse were prospectively sampled at intervals as depicted in Fig. 1 . All of them were considered contacts because they had entered the patient's room for more than 5 min per day and had performed procedures such as physical examination, drawing blood, and taking vital signs with the patient. Thirty members of the hospital staff working on the same floor who did not enter the room were selected as controls in order to document that P. carinii DNA is not normally carried by immunocompetent people. All of these people were apparently healthy, had not received medications with anti-P. carinii activity, and had no evidence of an immunosuppressive disease.
Sampling procedure and timing. Because the nasal turbinates are the first natural air filter encountered in humans, we elected to do deep-nasal-swab sampling of the nasal turbinates from persons in the study. A moist sterile cotton-swab was introduced deep into the nose, left there for 30 s, rotated, and withdrawn and placed in a sterile tube containing 300 l of saline. The first sample of the patient on day 1 was a nasopharyngeal aspirate and subsequent samples on days 5, 8, 12, 15, 26, 34, 41 , and 48, as well as all other respiratory samples in this study, were deep nasopharyngeal swabs. The mother was sampled on days 5, 8, 12, and 15, and the attending physician was sampled on days 8, 12, 34, and 41. The nurse was sampled once on day 8, and the 30 controls were also sampled once on day 34 as depicted in Fig. 1 . Samples were kept frozen at Ϫ20°C until DNA extraction.
DNA amplification. A volume of approximately 200 l of saline was examined for P. carinii by DNA amplification as previously described (14, 15) . Briefly, the samples were digested with proteinase K (20 mg ml
Ϫ1
) at 60°C in the presence of 10 mM EDTA and 0.5% sodium dodecyl sulfate. Total DNA was purified and concentrated by using the Pharma-Gen Clean Up system (Pharma-Gen, Madrid, Spain) and then recovered in a volume of 50 l.
For DNA amplification, the P. carinii f. sp. carinii oligonucleotide primers pAZ102-E (5Ј-GATGGCTGTTTCCAAGCCCA-3Ј) and pAZ102-H (5Ј-GTGT ACGTTGCAAAGTACTC-3Ј) were used. Amplification was carried out at 94°C for 1.0 min, 55°C for 1.0 min, and 72°C for 2.0 min for 40 cycles. In order to achieve a greater level of sensitivity and specificity, primers pAZ102-X (5Ј-GT GAAATACAAATCGGACTAGG-3Ј) and pAZ102-Y (5Ј-TCACTTAATATTA ATTGGGGAGC-3Ј), which are internal to the first set of primers and specific for P. carinii f. sp. hominis, were used in a second round of PCR (14, 15) . Thirty-five cycles of amplification were carried out under the same conditions as for the external primers. The PCR products were separated on 2.0% agarose gels and visualized with ethidium bromide. A P. carinii DNA amplification product of 267 bp was detected. Negative controls with no added template DNA were included after each sample to monitor for cross-contamination. A sample of human-derived P. carinii DNA was used as a positive control in each experiment. All manipulations during DNA extraction and amplification were performed in laminar flow cabinets by using disposable pipettes, tubes, and reagent aliquots to avoid contamination. DNA amplification was performed twice with each sample.
Antibody determinations. Antibody titer determinations were done in two 2-week interval serum samples from the patient and his contacts by comparing enzyme-linked immunosorbent assay (ELISA) readings obtained by using, respectively, a crude sonicate of P. carinii-infected mouse lungs (OD IML ) and a crude sonicate of normal P. carinii noninfected mouse lungs (OD NIML ) as solidphase antigen, as previously described (4, 5) . Briefly, P. carinii-infected and noninfected mouse lungs were sonicated, and the supernatant was then clarified by centrifugation and microfiltration (0.45 m, pore size), diluted to a protein concentration of ϳ10 g/ml in carbonate buffer, and used to coat microtiter wells in Linbro flat-bottom microtiter plates (Flow Laboratories, McLean, Va.). Plates were incubated tightly covered in a moist chamber at 37°C for 90 min to allow the antigen to adhere. Coated wells were blocked with 5% commercial nonfat dry milk in phosphate-buffered saline (PBS) for 1 h at 37°C or overnight at 4°C. Sera were diluted 1:50 in PBS containing 0.05% Tween 20 (PBS-T; Sigma, St. Louis, Mo.), and 50 l of each serum sample per well was incubated overnight at 4°C. Plates were then washed three times with PBS-T, and bound antibody was detected by using goat anti-human IgG or IgM conjugated to alkaline phosphatase (Jackson Immunoresearch Laboratories, West Grove, Pa.) diluted 1:5,000 in PBS-T. After a 4-h incubation period at 37°C, the plates were washed four times with PBS-T and developed by the addition of p-nitrophenyl phosphate (Sigma) at a concentration of 1 mg/ml in diethanolamine buffer. This ELISA was previously standardized by using a variety of monoclonal and polyclonal antibodies known to be specific for P. carinii. 
RESULTS
Fifty nasopharyngeal swab samples from the patient (n ϭ 9), the mother (n ϭ 6), the attending nurse (n ϭ 1), the attending physician (n ϭ 4), and the 30 controls were analyzed by DNA amplification as depicted in Fig. 1 . Of 11 samples taken from the three contact individuals, 4 were positive for P. carinii DNA. The 30 hospital personnel (controls) who had not entered the patient's room were sampled once, and none of these individuals was positive for P. carinii DNA. None of the contacts developed symptoms suggestive of P. carinii disease during the period of the study, and their antibody titers remained stable. Antibody titers (OD IML /OD NIML ) obtained in the patient showed 0.44/0.17 to be uninterpretable in the first serum sample drawn on day 1 and positive on the second serum sample on day 39 (0.18/0.05). Serum titers from the patient contacts were positive in the first (day 11) and second (day 29) samples in the mother (0.50/0.10 and 0.62/0.12) and in the attending physician on days 12 and 29 (0.47/0.14 and 0.42/0.13). The nurse was possibly positive in the first reading on day 12 (0.30/0.15) and positive in the second reading on day 29 (0.26/ 0.09). Sera from the controls for these days were not available.
DISCUSSION
The detection of P. carinii f. sp. hominis DNA in deep-nares swab samples from health care workers in contact with a patient with PCP suggests the air spread of P. carinii from the patient and inhalation by his contacts, supporting the concept of airborne person-to-person transmission of P. carinii (1, 2, 6-8, 12, 13; Giron et al., Letter). Previous attempts to document person-to-person transmission of P. carinii by amplifying P. carinii sequences in induced sputum and oropharyngeal washing samples from people in contact with PCP patients have not detected evidence of P. carinii DNA (9, 10) . In this study, we elected to sample the nasal cavities of the patient, his contacts, and the control group because the nasal turbinates constitute the first air breath filter in the respiratory system. We believe that deep nasal swabs or nasopharyngeal aspirates should be preferred as a research tool for detecting P. carinii DNA in individuals who don't have clinical evidence of PCP. Whether the finding of P. carinii DNA in the nares of the contacts of this patient with PCP indicates the presence of infectious material and whether the contacts could be a vector for disease transmission remains to be determined. Unfortu- P. carinii was cleared from the nares of the mother and the physician in relation to the clearing of P. carinii from the patient samples. Therefore, the presence of P. carinii DNA in immunocompetent contact individuals was self-limited and transitory and might have been the result of continuous inhalation of P. carinii particles, indicating surface (nares) contamination and carriage rather than an active infectious process.
All of the 30 immunocompetent health care personnel who had not entered the patient's room tested negative by PCR, suggesting that the transmission of P. carinii is not common among healthy adults unless they are exposed to a patient with PCP (H. S. Oz and W. T. Hughes, American Lung Association Conference and Symposium, abstr. 7, 1999) . No other patients with PCP were diagnosed in this pediatric hospital during the time of the study.
Given the index patient's young age (8 months), the antibody titers determined in the crude ELISA format is likely an indication that the patient mounted an immune response during a primary infection with P. carinii. All adult contacts were also antibody positive. However, they did not experience a rise in antibody titers after P. carinii DNA was detected in their nares. This lack of serological response is more consistent with transient colonization of the contacts rather than with an active infectious process. Adults normally exhibit an antibody response to the major antigenic determinants present in the P. carinii wall (11) .
In summary, this study provides molecular evidence that airborne person-to-person transmission of P. carinii sp. f. hominis is possible, thus suggesting that patients with PCP should not come into close contact with immunocompromised persons. Immunocompromised patients who are not receiving PCP prophylaxis should not enter the room of a patient with PCP. The data show that the immunocompetent contacts of patients with PCP can acquire transient colonization by the organism. A potential role, if any, of immunocompetent hosts transiently colonized with P. carinii as vectors of the disease warrants further investigation.
